Literature DB >> 21151158

The distinct role of guanine nucleotide exchange factor Vav1 in Bcl-2 transcription and apoptosis inhibition in Jurkat leukemia T cells.

Jie Yin1, Ya-juan Wan, Shi-yang Li, Ming-juan Du, Cui-zhu Zhang, Xing-long Zhou, You-jia Cao.   

Abstract

AIM: To investigate a novel function of proto-oncogene Vav1 in the apoptosis of human leukemia Jurkat cells.
METHODS: Jurkat cells, Jurkat-derived vav1-null cells (J.Vav1) and Vav1-reconstituted J.WT cells were treated with a Fas agonist antibody, IgM clone CH11. Apoptosis was determined using propidium iodide (PI) staining, Annexin-V staining, DNA fragmentation, cleavage of caspase 3/caspase 8, and poly (ADP-ribose) polymerase (PARP). Mitochondria transmembrane potential (ΔΨ(m)) was measured using DiOC(6)(3) staining. Transcription and expression of the Bcl-2 family of proteins were evaluated using semi-quantitative RT-PCR and Western blot, respectively. Bcl-2 promoter activity was analyzed using luciferase reporter assays.
RESULTS: Cells lacking Vav1 were more sensitive to Fas-mediated apoptosis than Jurkat and J.WT cells. J.Vav1 cells lost mitochondria transmembrane potential (ΔΨ(m)) more rapidly upon Fas induction. These phenotypes could be rescued by re-expression of Vav1 in J.Vav1 cells. The expression of Vav1 increased the transcription of pro-survival Bcl-2. The guanine nucleotide exchange activity of Vav1 was required for enhancing Bcl-2 promoter activity, and the Vav1 downstream substrate, small GTPase Rac2, was likely involved in the control of Bcl-2 expression.
CONCLUSION: Vav1 protects Jurkat cells from Fas-mediated apoptosis by promoting Bcl-2 transcription through its GEF activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21151158      PMCID: PMC4003318          DOI: 10.1038/aps.2010.185

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  42 in total

Review 1.  Pathways of apoptosis in lymphocyte development, homeostasis, and disease.

Authors:  Jeffrey C Rathmell; Craig B Thompson
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

Review 2.  Vav proteins, adaptors and cell signaling.

Authors:  X R Bustelo
Journal:  Oncogene       Date:  2001-10-01       Impact factor: 9.867

3.  CD4-Lck through TCR and in the absence of Vav exchange factor induces Bax increase and mitochondrial damage.

Authors:  Loretta Tuosto; Barbara Marinari; Enza Piccolella
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

4.  NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells.

Authors:  Caroline A Heckman; John W Mehew; Linda M Boxer
Journal:  Oncogene       Date:  2002-05-30       Impact factor: 9.867

5.  Caspase-dependent cleavage and inactivation of the Vav1 proto-oncogene product during apoptosis prevents IL-2 transcription.

Authors:  T G Hofmann; S P Hehner; W Dröge; M L Schmitz
Journal:  Oncogene       Date:  2000-02-24       Impact factor: 9.867

6.  Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation.

Authors:  B Aghazadeh; W E Lowry; X Y Huang; M K Rosen
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

7.  Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim.

Authors:  David A Hildeman; Yanan Zhu; Thomas C Mitchell; Philippe Bouillet; Andreas Strasser; John Kappler; Philippa Marrack
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

Review 8.  Rho family GTPases and their regulators in lymphocytes.

Authors:  Victor L J Tybulewicz; Robert B Henderson
Journal:  Nat Rev Immunol       Date:  2009-08-21       Impact factor: 53.106

9.  Vav1 is a component of transcriptionally active complexes.

Authors:  Martin Houlard; Ramachandran Arudchandran; Fabienne Regnier-Ricard; Antonia Germani; Sylvie Gisselbrecht; Ulrich Blank; Juan Rivera; Nadine Varin-Blank
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

10.  Deficiency of small GTPase Rac2 affects T cell activation.

Authors:  H Yu; D Leitenberg; B Li; R A Flavell
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

View more
  6 in total

1.  Vav1 in hematologic neoplasms, a mini review.

Authors:  Matthew J Oberley; Deng-Shun Wang; David T Yang
Journal:  Am J Blood Res       Date:  2012-01-01

2.  Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction.

Authors:  Yi Jiang; Ze-Hong Miao; Lei Xu; Bing Yu; Jing-Xu Gong; Lin-Jiang Tong; Yi Chen; Zhao-Li Zhou; Hong-Chun Liu; Yi Wang; Yue-Wei Guo; Jian Ding
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

3.  Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.

Authors:  Maša Umiċeviċ Mirkov; Jing Cui; Sita H Vermeulen; Eli A Stahl; Erik J M Toonen; Remco R Makkinje; Annette T Lee; Tom W J Huizinga; Renee Allaart; Anne Barton; Xavier Mariette; Corinne Richard Miceli; Lindsey A Criswell; Paul P Tak; Niek de Vries; Saedis Saevarsdottir; Leonid Padyukov; S Louis Bridges; Dirk-Jan van Schaardenburg; Tim L Jansen; Ellen A J Dutmer; Mart A F J van de Laar; Pilar Barrera; Timothy R D J Radstake; Piet L C M van Riel; Hans Scheffer; Barbara Franke; Han G Brunner; Robert M Plenge; Peter K Gregersen; Henk-Jan Guchelaar; Marieke J H Coenen
Journal:  Ann Rheum Dis       Date:  2012-12-11       Impact factor: 19.103

4.  Estrogen induces Vav1 expression in human breast cancer cells.

Authors:  Ming-juan Du; Xiang-dong Chen; Xiao-li Zhou; Ya-juan Wan; Bei Lan; Cui-zhu Zhang; Youjia Cao
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

5.  Vav1 fine tunes p53 control of apoptosis versus proliferation in breast cancer.

Authors:  Shulamit Sebban; Marganit Farago; Dan Gashai; Lena Ilan; Eli Pikarsky; Ittai Ben-Porath; Shulamit Katzav
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

6.  Vav1 Promotes B-Cell Lymphoma Development.

Authors:  Batel Shalom; Marganit Farago; Yaser Salaymeh; Shulamit Sebban; Eli Pikarsky; Shulamit Katzav
Journal:  Cells       Date:  2022-03-10       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.